Man with Parkinson's stood up and walked away after an injection. The drugmaker's stock still fell 20%
A man with Parkinson's who couldn't get up from a chair walked out through the door on his own after a year of treatment with his own cells. The company behind the treatment raised $140.6 million in its IPO, and three weeks later its stock is 20% cheaper, even though there hasn't been a single piece of bad news.

Key points
A man with Parkinson's who couldn't get up from a chair walked away on his own after a year of treatment with his own cells.
On the same day, a company treating eczema also priced its IPO, and the market paid full price for its shares - Aspen didn't get that.
Making a single dose takes about five months, and it starts with a piece of skin just three millimeters across.
The prospectus states when the company will run out of money, and the CEO confirmed it in an interview.
At the end of April 2027, OrbiMed, ARCH and Gilead Sciences will be able to sell for the first time.
A drug that brought people to tears, and a stock nobody wanted at full price
In a video taken before treatment, a man with Parkinson's disease struggles unsuccessfully to get up from a chair, speaks quietly and has a blank expression. In a video a year later, he stands up, walks through a doorway and down the hall with a smooth gait. The head of the company that made his treatment says the team was in tears. And between the two clips, there's nothing but a single injection into the brain, filled with cells grown from a piece of the patient's own skin.
The company is called Aspen Neuroscience $ASPE and priced its IPO on 29. 10. 2026. It's the kind of story anyone would sell, yet it made surprisingly little impression on the stock market. Underwriters had to settle for the lowest price the company had been willing to accept, and since its first day of trading on 30. 10. 2026, the price has only fallen. From the IPO price of $15, it's down to $12.01 USD as of 18. 11. 2026, a fifth lower. The company hasn't published a single piece of bad news in that time.
It's even more striking by comparison. Another biotech company, Bambusa Therapeutics, which is developing eczema drugs, priced its IPO on the same day. Demand for its shares was so strong that it increased the offering and priced it in the middle of the range. So investors who make their living in biotech and understand it better than anyone else said, on the same day and under the same conditions: we'll pay full price for eczema, but not for Parkinson's.
Those people don't doubt the video. They doubt what's between the video and a profit. And the company's prospectus contains one sentence that explains it better than all the clinical data: it says when the company will need money again.